Comparative  Study of  Serum levels of  Granzyme H & Estrogen In Patients  Suffering From  Breast Cancer by Tahbaz lahafi, Behnoosh et al.
 




Comparative  Study of  Serum levels of  Granzyme H & Estrogen In Patients  
Suffering From  Breast Cancer     
 
Behnoosh Tahbaz lahafi¹, Houshang Amirrasouli*¹, Mohammad-Esmaeil Akbari², Saeed 
Namaki¹, Faranak Kazerouni¹, Ali Rahimipour¹, Jahangir Mohammadzade¹ 
 
¹ Proteomics Research Center,  Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 
²Cancer Research Center,Shohada Hospital, Shahid Behesht University of Medical Sciences,Tajrish,Tehran,Iran. 
 




     GranzymeH is a functional cytotoxic serine protease of NK cell granules,which expands the cell death-
inducing repertoire of innate immune system.The purpose of this study was to determine 
GranzymeH(GZMH)level in breast cancer(BC) and healthy women.This study was performed on 30 patients 
with BC and 30 healthy women.Serum GZMH and Estrogen levels were measured in cancer patients  and 
healthy women subsequently using ELISA and Radioimmunoassay(RIA) methods. Mean GZMH value was 
lower in BC than healthy women(p<0.0001) and  mean Estrogen level was  higher  in BC patients  in 
comparison to healthy women (p<0.003).Our finding indicates probability of existance of suppressor or a 
problem in production of GZMH in cancer patients. 
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INTRODUCTION 
     Breast  cancer is  fairly  common, because of  
its well  publicized nature, and potential for  
lethality, breast cancer is arguably  the most 
frightening  type of cancer diagnosis  someone 
can receive [1]. Breast cancer (BC) is the most 
prevalent cancer in Iranian women and the fifth 
most common cause of  cancer-related death in 
Iran[2]. Experimental data strongly suggest that 
estrogen have a role in the development and 
growth of breast cancer.[3].Estrogen may be 
implicated in breast cancer risk because of 1)its 
role in stimulating breast cell division.2)its work 
during the critical period of breast growth and 
development.3)its effect on other hormones  that 
stimulate breast cell division and 4)its support of 
the growth of estrogen-responsive[4].Cytotoxic T 
cells(CTL) and natural killer (NK)cells are 
indispensable factors in the body’s ongoing 
defence against viral infection and tumor 
development.CTL/NK cells recognize and kill 
infected or aberrant target cells by two major 
pathways:either through introduction of a battery 
of proteases-call granzymes-to the target cell 
cytosol,or through TNF superfamily-dependent 
killing[5].Granzymes are chymotrypsin (CHT)-
like serine proteases expressed in the secretary 
granules of CTLs and NK cells.Upon the 
encounter of diseased cells,granzymes are 
released by exocytosis,a long with other granular 
proteins,in to the immunological synapse where 
they are subsequently taken up to rogue cells via 
the actions of the pore forming protein 
perforin(PFN).Once in the target cell 
cytosol,granzymes proteolytically cleave a variety 
of death substrates that,in turn ,lead to eventual 
cell suicide[6]. The granule-mediated pathway is 
often the predominant pathway for CTL and NK 
cell-induced cell death [7].GZMH is 
constitutively expressed in human resting NK 
cells.This suggests GZMH may play an important 
role in cytolysis induced by human 
NKcells[8].GZMH is thus a functional cytotoxic 
serine protease of NK cell granules,which 
expands the cell death-inducing repertoire of 
innate immune system[9].The death induced by 
GZMH displays many features of apoptosis, 
inducing DNA degradation,chromatin 
condensation, mitochondrial depolarization, and 
generation of reactive oxygen species[10]. The 
 




purpose of this study was to determine 
GranzymeH  level in breast cancer(BC) and 
healthy women. 
 MATERIALS AND METHODS 
     In this study 30 patients with BC who referred 
to Cancer Research Center,Shahid Beheshti 
University of Medical Sciences and 30 healthy 
women as the control group were recruited.In our 
study clinical staging of the breast cancer patients 
was base on the American Joint Committee on 
Cancer (AJCC ) classification,with refrence to 
which 10% of the patients were in stage I,73.3% 
were in stage II,16.7% were in stageIII[11 ]. 
The exclusion criteria for all subjects enrolled in 
this study were presence of immunological 
disorder , acute / chronic inflammatory disease 
and history of immunosuppressive or radiation 
therapy [12].All participants gave their written 
informed consent and agreed to proceed with 
study protocol.4 cc blood was collected from the 
subjects , serum was isolated and stored at-80˚C 
.The concentration of serum estrogen of all study 
subjects was measured using RIA method 
(Biosource ,KIP0629). serum GZMH was 
measured using the ELISA method (CUSABIO 
,GZMH-E17366h). 
Statistical  Analysis 
Results were expressed as mean±SD of 
experiments. Student's t-test was used for 
comparison of the means between two groups, 
and one-way ANOVA for comparison between 
multiple groups. To assess correlation between 
GranzymeH and Estrogen,age,cancer stage 
correlation bivariate test was performed. For all 
tests, P<0.05 was considered statistically 
significant. Data were analyzed using SPSS 
software version 16. 
 
RESULTS 
   As show in table1 in this study the mean age of 
subjects was 36.2±8.12(ages 24-54 years). 
 
        Table1: age rang of participated women 
Age 
Min Max Mean SD 
24 54 36.2 8.12 
 
Based on  comparing the obtained results with the 
control group GZMH   was significantly lower in 
the cancer patients (71.6±12.2  vs 96.16±13.14 
pg/ml  p<0.0001).Estrogen level was statistically 
higher in patients  than the control group 
(107.5±23.8 vs 90.5±14.8 pg/ml  p<0.003 ).There 
was no significant correlation between cancer 
stage and Estrogen level in patient group. A weak 
significant inverse correlation was seen between 
estrogen and GZMH (r=-0.3 p<0.02). 
 
DISCUSSION 
     NK cells express the strongly proapoptotic 
GZMA and GZMB along with perforin. However 
since other granzymes of NK cell like GZMH has 
so far received little attention .We decided to 
determine GZMH level in breast cancer 
patients.[9]According to our finding GZMH level 
was significantly lower in patients than the 
control group this result in consistent with the 
observation of Razavi NZ et al who reported 
lower GZMH level in cancer patients before  and 
after chemotherapy as compare to normal control 
subjects.[13]Our finding can be an indication of 
the importance of granzymes ;a major 
components of granules of cytolytic lymphocyte, 
NK  and cytotoxic T,and its possible contribution 
as an alternative cytotoxic effector protease to NK 
cell function in tumor elimination[13]. Razavi NZ 
et al showed that level of GZMH was increased in 
BC patients after chemotherapy which is probably 
result of high apoptotic ratio in cancer tissues 
indicative of a favourable patient outcome [13]. In 
consistence with previous research works in our 
study estrogen level was higher in BC patients in 
comparison to the control group. (p<0.003) It is 
found that estrogen induction of PI-9 (Proteinase 
inhibitor 9) may reduce the ability of cytolytic 
lymphocyte mediated immune surveillance to 
destroy newly transformed cells [14]. 
 
CONCLUSION 
     We found a weak  inverse correlation between 
GZMH and estrogen which can be indicative of 
inductive effect of estrogen on GZMH. Further 
studies are required for understanding the exact 
mechanism related to decreased level of GZMH 
in BC patients. In conclusion our finding indicates 
probability of existance of suppressor or a 
problem in production of GZMH in cancer 
patients. 
ACKNOWLEDGMENTS 
     This article is a rewriting of a MSc  Thesis. 
 






1.Evert Jessica,MD,edited by Benjamin 
McDonald. Breast cancer :Introduction. national 
breast cancer foundation.jun 3oth 2010. 
2.Atieh Akbari,Zahra Razzaghi, Fatemeh 
Homaee,Parity and breastfeeding are preventive 
measures against breast cancer in  Iranian women. 
Japanese Breast Cancer Society 2011;18:51-55. 
3. Clemon Mark and Goss Paul, Franklinh  
Epstain, M.D.,Editor, Estrogen and the risk of 
Breast Cancer, The New England Journal of 
Medicine, 2001, No. 4 ,Vol. 344. 
4.Program on breast cancer and environmental 
risk factors : Cornell University  (Envirocancer. 
cornell. edu). 
5. Cullen SP & et al . Granzyms in cancer and  
Immunity . published Cell Death Differ 2010. 
6. Fellows E, Granzyme H anovel   cell-death-
inducing serine protease ,The American Society 
of Hematology.8.9.2007. 
7. Jiang X,Orr BA,Kranz DM,Shapio DJ. 
Esterogen  induction of the granzyme 
Binhibitor,proteinase      inhibitor9,protects cells 
against  apoptosis mediated by  cytotoxic T 
lymphocytes and natural       killer cell. 
Endocrinology : 2006,147:1419-1426. 
 8.Qiang Hou,Tongbiao Zhao,Honglian Zhang 
and et al, Granzyme H  induces         apoptosis of 
target tumor cells charecterized  by  DNA 
fragmentation and  BID –dependent  mitocondrial 
damage , Molecular Immunology , 2008 ; 45 , 
1044-1055 (PMID:17765974)  
9. Fellows E,Gil-Parrado S,Jenne De and et al, 
Natural  killer  cell-drived  human  GrmH  induce       
an  alternative  caspase-indepent cell  
deathProgram,Journal of The American Society of     
Hematology, 2007;110:544-552  
(PMID:17409270)  
10. Fehniger Todd A, Orphan granzyme turned 
lethal weapon ,Blood journal(The American 
Society of Hematology), 2007;110,475-476. 
11. Jardines Lori, Bruce G.Haffty  , Fisher Paul 
and et al,Breasr Cancer Overview,Risk Factors, 
Screening, Genetic testing , and      Prevention, 
chapter8 
12.Tokmadzic VS ,Tomas MI ,Sotosek S 
,Laskarin G and et al .Different Perforin 
Expression in Peripheral Blood and Prostate 
Tissue in Patients with Benign Prostatic 
Hyperplasia and Prostate Cancer. Scand J 
Immunology,2011 oct;74(4):368-376. 
13. Razvi Naheed z, Rukhshan  khurshid, saeed 
ahmad nagra ,To  study the significance   of       
apoptosis  enzyme granzyme H  in breast cancer 
patients,J Ayub Med Coll     
abbottabad,2008;page 84-86. 
14. Jiang X ,Ellisa SJ,Alarid ET and et al, 
Interplay  between the  levels of estrogen and 
estrogen controls  the level of the granzyme     
inhibitor , proteinase  inhibitor9 and susceptibility 
to immune surveillance by natural  killer       cells 
, 2007,Oncogene 26,4106-4114.  
